{"id":"pathogen-reduction-process","safety":{"commonSideEffects":[{"rate":null,"effect":"Reduced platelet viability or function"},{"rate":null,"effect":"Hemolysis in treated red blood cells"},{"rate":null,"effect":"Coagulation factor reduction in treated plasma"}]},"_chembl":{"chemblId":"CHEMBL5816807","moleculeType":null,"molecularWeight":"342.35"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Pathogen reduction processes use methods such as photochemical treatment (e.g., with psoralens and UV light) or other inactivation techniques to neutralize a broad spectrum of pathogens including enveloped and non-enveloped viruses, bacteria, and parasites in blood components. This reduces the risk of transfusion-transmitted infections while maintaining the hemostatic function of the treated blood product.","oneSentence":"A pathogen reduction technology that inactivates viruses, bacteria, and other pathogens in blood products through chemical or physical treatment to improve transfusion safety.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:51.458Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pathogen reduction of blood components (red blood cells, platelets, plasma) for transfusion"}]},"trialDetails":[{"nctId":"NCT03037164","phase":"PHASE3","title":"INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections","status":"ACTIVE_NOT_RECRUITING","sponsor":"Cerus Corporation","startDate":"2017-05-11","conditions":"Anemia","enrollment":692},{"nctId":"NCT03459287","phase":"PHASE3","title":"Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients","status":"COMPLETED","sponsor":"Cerus Corporation","startDate":"2018-12-05","conditions":"Anemia","enrollment":581},{"nctId":"NCT07152379","phase":"PHASE2","title":"Challenge Transfusion of INTERCEPT Pathogen Reduced Red Blood Cells (RBCs) in Subjects With or Without Pre-existing Antibodies to INTERCEPT RBCs","status":"NOT_YET_RECRUITING","sponsor":"Cerus Corporation","startDate":"2026-01-01","conditions":"Transfusion Reaction, Hemolytic","enrollment":10},{"nctId":"NCT04457635","phase":"NA","title":"Effect of a 'Rapid-Return-to-work Program' in Mild Mental Disorders.","status":"COMPLETED","sponsor":"The Hospital of Vestfold","startDate":"2013-09","conditions":"Mental Disorder","enrollment":300},{"nctId":"NCT03486054","phase":"NA","title":"INTERCEPT Safety Evaluation in Anemic Patients","status":"WITHDRAWN","sponsor":"Swiss Transfusion SRC","startDate":"2019-06","conditions":"Anemia","enrollment":""},{"nctId":"NCT01789762","phase":"PHASE4","title":"Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process","status":"COMPLETED","sponsor":"Etablissement Français du Sang","startDate":"2013-05","conditions":"Aplasia With Expected Thrombocytopenia","enrollment":842},{"nctId":"NCT01642563","phase":"PHASE3","title":"Italian Platelet Technology Assessment Study","status":"TERMINATED","sponsor":"Centro Nazionale Sangue","startDate":"2010-10","conditions":"Leukemia, Lymphoma","enrollment":456}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Pathogen reduction process","genericName":"Pathogen reduction process","companyName":"Etablissement Français du Sang","companyId":"etablissement-fran-ais-du-sang","modality":"Biologic","firstApprovalDate":"","aiSummary":"A pathogen reduction process inactivates viruses, bacteria, and other pathogens in blood products through physical or chemical treatment to improve transfusion safety. Used for Reduction of transfusion-transmitted viral infections in plasma, Reduction of transfusion-transmitted viral and bacterial infections in platelet concentrates, Reduction of transfusion-transmitted infections in red blood cell products.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}